SfN 2025 – High-Content Imaging Platforms for Assessing Neuroplasticity in Early-Stage Drug Discovery

Accelerating Neuroplasticity Screening with Scalable in vitro Models

Structural and functional neuroplasticity is a key driver of brain development and adaptation—but studying it effectively at early stages of drug discovery remains challenging. This poster highlights Sygnature Discovery’s semi-automated high-content imaging platform that quantifies neurite outgrowth across PC12, SH-SY5Y, and primary neuron models.

The result? A robust, scalable tool for phenotypic screening of neuroplasticity modulators—accelerating the identification of new therapies for neuropsychiatric and neurodegenerative disorders, with flexibility to expand into metabolism, neuroinflammation, and beyond.

👉 Download the free poster to see how this platform bridges early discovery and translational neuroscience.